417 terminated. 417 Phase 1, 147 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 417 | Terminated 417 |
| Phase 2 | 147 | Terminated 147 |
Follow Gastrointestinal Diseases: new trials by email Literature Review of Gastrointestinal Diseases trials Research Report on Gastrointestinal Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 4SCAR-CD44v6 T Cell Therapy Targeting Cancer CD44v6-specific CAR gene-engineered T cells - Cancers Which Are CD44v6 Positive | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 100 | 2026-06-01 | 2026-11-03 |
| A First-in-Human Study of BB-TL1A-VIAL-HLE in Healthy Adults and People With Ulcerative Colitis BB-TL1A-VIAL-HLE - Ulcerative Colitis (UC) | Phase 1 | Terminated | Vial Australia Pty Ltd | 16 | 2025-06-23 | 2026-01-22 |
| Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors BL-M17D1 - Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer | Phase 1 | Terminated | SystImmune Inc. | 3 | 2025-04-10 | 2026-09-22 |
| A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas BI 765049 - Colorectal Carcinoma, Gastric Carcinoma | Phase 1 | Terminated | Boehringer Ingelheim | 14 | 2025-03-28 | 2026-10-27 |
| A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. PF-07985045, Gemcitabine, Nab-paclitaxel - Carcinoma, Pancreatic Ductal, Colorectal Neoplasms | Phase 1 | Terminated | Pfizer | 30 | 2024-12-10 | 2026-05-22 |
| A Study of NP-201 Acetate Injection in Healthy Adult Volunteers and in Patients With Mild-To-Moderate Active Ulcerative Colitis NP-201 acetate injection (Part A), Placebo - Healthy Adult Volunteers, Active Ulcerative Colitis | Phase 1 | Terminated | NIBEC Co., Ltd. | 35 | 2024-11-25 | 2026-06-23 |
| A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer PF-07921585, Sasanlimab - Non Small Cell Lung Cancer, Bladder Cancer | Phase 1 | Terminated | Pfizer | 4 | 2024-11-11 | 2026-03-23 |
| A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation PRT7732 - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Terminated | Prelude Therapeutics Incorporated | 42 | 2024-11-04 | 2026-02-02 |
| A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation AZD0022, Cetuximab - Advanced Solid Tumours, Non-Small Cell Lung Cancer (NSCLC) | Phase 1 | Terminated | AstraZeneca | 17 | 2024-10-18 | 2026-03-18 |
| First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers ATX-559 - Advanced Solid Tumors, Breast Cancer Recurrent | Phase 1 | Terminated | Accent Therapeutics | 17 | 2024-10-11 | 2026-02-24 |
| A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines. PF-07826390, sasanlimab, SOC (anti-PD-1 + platinum -based chemo) - Neoplasms, Non-small-cell Lung Cancer | Phase 1 | Terminated | Pfizer | 10 | 2024-09-06 | 2026-02-23 |
| A Study of SGN-MesoC2 in Advanced Solid Tumors PF-08052666 - Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms | Phase 1 | Terminated | Seagen, a wholly owned subsidiary of Pfizer | 19 | 2024-08-02 | 2026-07-07 |
| A Study of PHN-010 in Patients With Advanced Solid Tumors PHN-010 - Lung Cancer, Colon Cancer | Phase 1 | Terminated | Pheon Therapeutics | 26 | 2024-07-01 | 2026-01-29 |
| A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors ACTM-838 - Solid Tumor | Phase 1 | Terminated | Actym Therapeutics, Inc. | 10 | 2024-06-05 | 2025-10-15 |
| A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination PF-07329640, sasanlimab, bevacizumab - Advanced or Metastatic Solid Tumors, Non-Small Cell Lung Cancer | Phase 1 | Terminated | Pfizer | 4 | 2024-05-09 | 2024-11-06 |
| A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers BGB-3245, Panitumumab - Colorectal Cancer, Pancreatic Ductal Cancer | Phase 1 | Terminated | MapKure, LLC | 13 | 2024-04-18 | 2025-04-20 |
| A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors ASP4396 - Solid Tumor | Phase 1 | Terminated | Astellas Pharma Inc | 60 | 2024-04-16 | 2026-10-23 |
| A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors NKT3447 - Solid Tumor, Solid Tumor, Adult | Phase 1 | Terminated | NiKang Therapeutics, Inc. | 23 | 2024-02-23 | 2025-09-25 |
| A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6 BI 765049, Ezabenlimab - Gastrointestinal Cancer, Lung Cancer | Phase 1 | Terminated | Boehringer Ingelheim | 21 | 2024-02-16 | 2026-10-14 |
| A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors PF-07820435, Sasanlimab - Neoplasms, Non-small-cell Lung Cancer | Phase 1 | Terminated | Pfizer | 9 | 2024-02-08 | 2025-09-17 |
Showing 20 of 417. Sign in to see all of them.
Colorectal Neoplasms (188) · Carcinoma, Non-Small-Cell Lung (102) · Stomach Neoplasms (87) · Colonic Neoplasms (64) · Melanoma (58) · Breast Neoplasms (52) · Neoplasms (50) · Ovarian Neoplasms (50) · Neoplasm Metastasis (49) · Rectal Neoplasms (49) · Squamous Cell Carcinoma of Head and Neck (48) · Esophageal Neoplasms (46) · Pancreatic Neoplasms (46) · Carcinoma, Renal Cell (38) · Lung Neoplasms (35)
Digestive System Diseases (413) · Neoplasms by Site (336) · Digestive System Neoplasms (332) · Gastrointestinal Neoplasms (322) · Intestinal Diseases (315) · Neoplasms (296) · Colonic Diseases (256) · Intestinal Neoplasms (252) · Rectal Diseases (230) · Neoplasms by Histologic Type (153) · Neoplasms, Glandular and Epithelial (128) · Respiratory Tract Diseases (128) · Lung Diseases (126) · Respiratory Tract Neoplasms (126)
pembrolizumab (33) · Cetuximab (22) · Capecitabine (21) · Fluorouracil (20) · Oxaliplatin (17) · Irinotecan (16) · Leucovorin (13) · Nivolumab (13) · Bevacizumab (12) · Radiotherapy (12) · Cyclophosphamide (11) · Docetaxel (11) · Cisplatin (10) · IFL protocol (10) · Gemcitabine (9)
National Cancer Institute (NCI) (20) · Pfizer (20) · Incyte Corporation (9) · Novartis Pharmaceuticals (9) · Merck Sharp & Dohme LLC (7) · Bristol-Myers Squibb (6) · Hoffmann-La Roche (6) · Seagen Inc. (6) · Amgen (5) · Washington University School of Medicine (5) · AbbVie (4) · Anthony Lembo (4) · AstraZeneca (4) · Boehringer Ingelheim (4) · Mirati Therapeutics Inc. (4)
United States (321) · Spain (45) · Australia (44) · United Kingdom (32) · Canada (31) · France (30) · South Korea (26) · Belgium (25) · Germany (23) · Japan (19) · Italy (18) · Netherlands (16) · Taiwan (16) · China (11) · Israel (10)
Amy Lightner, MD (5) · David S Schrump, M.D. (5) · Bill Arana (3) · Andrew Ko, MD (2)
PMID 31527168, PMID 18197583, PMID 18845990, PMID 19525947, PMID 19738454, PMID 20305636, PMID 21516509, PMID 23553066, PMID 24285980, PMID 25290091, PMID 25627002, PMID 27784746, PMID 28576557, PMID 28677263, PMID 29322091, PMID 29735994, PMID 29808006, PMID 29934438, PMID 30139840, PMID 30858085, PMID 30911664, PMID 31802410, PMID 32410080, PMID 32524319, PMID 32598257, PMID 32788205, PMID 32819975, PMID 32891715, PMID 33016924, PMID 33039812, PMID 33355229, PMID 33677480, PMID 33686452, PMID 34686340, PMID 34951522, PMID 35176457, PMID 35247086, PMID 35299273, PMID 35429391, PMID 35444059, PMID 35493516, PMID 35537408, PMID 35930441, PMID 36030462, PMID 36322714, PMID 36384095, PMID 36738333, PMID 36787089, PMID 36800443, PMID 36940261
2017 (11), 2019 (8), 2018 (7), 2023 (6), 2014 (4), 2015 (4), 2016 (4), 2009 (2), P30CA043703 (2), P30CA068485 (2), U01CA121947 (2), N01CM00100 (1), N01CM62204 (1), N01CN35157 (1), P30CA006927 (1)